221 related articles for article (PubMed ID: 37150034)
1. The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease.
Gao Y; Su X; Xue T; Zhang N
Biomed Pharmacother; 2023 Jul; 163():114598. PubMed ID: 37150034
[TBL] [Abstract][Full Text] [Related]
2. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy.
Wang E; Wang L; Ding R; Zhai M; Ge R; Zhou P; Wang T; Fang H; Wang J; Huang J
Pharmacol Res; 2020 Jul; 157():104831. PubMed ID: 32339782
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease.
Hu Y; Tang W; Liu W; Hu Z; Pan C
Drug Des Devel Ther; 2022; 16():1605-1620. PubMed ID: 35669284
[TBL] [Abstract][Full Text] [Related]
4. [Research advances on astragaloside-IV in treatment of diabetes mellitus and its complications pharmacological effects].
You LZ; Lin YX; Fang ZH; Shen GM; Zhao JD; Wang TT
Zhongguo Zhong Yao Za Zhi; 2017 Dec; 42(24):4700-4706. PubMed ID: 29493134
[TBL] [Abstract][Full Text] [Related]
5. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L
BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386
[TBL] [Abstract][Full Text] [Related]
6. Effect of astragaloside IV on indoxyl sulfate-induced kidney injury in mice via attenuation of oxidative stress.
Ji C; Luo Y; Zou C; Huang L; Tian R; Lu Z
BMC Pharmacol Toxicol; 2018 Sep; 19(1):53. PubMed ID: 30176914
[TBL] [Abstract][Full Text] [Related]
7. Chinese herbal medicine and its active compounds in attenuating renal injury
Liu P; Zhu W; Wang Y; Ma G; Zhao H; Li P
Front Endocrinol (Lausanne); 2023; 14():1142805. PubMed ID: 36942026
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation.
Zhang Y; Tao C; Xuan C; Jiang J; Cao W
Oxid Med Cell Longev; 2020; 2020():9542165. PubMed ID: 32855769
[TBL] [Abstract][Full Text] [Related]
9. Research review on the pharmacological effects of astragaloside IV.
Li L; Hou X; Xu R; Liu C; Tu M
Fundam Clin Pharmacol; 2017 Feb; 31(1):17-36. PubMed ID: 27567103
[TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells.
Qi W; Niu J; Qin Q; Qiao Z; Gu Y
Cell Stress Chaperones; 2014 Jan; 19(1):105-14. PubMed ID: 23719694
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of Astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats.
Ju Y; Su Y; Chen Q; Ma K; Ji T; Wang Z; Li W; Li W
Biomed Pharmacother; 2019 Jan; 109():84-92. PubMed ID: 30396095
[TBL] [Abstract][Full Text] [Related]
12. Research progress on the antitumor effects of astragaloside IV.
Zhou R; Guo T; Li J
Eur J Pharmacol; 2023 Jan; 938():175449. PubMed ID: 36473596
[TBL] [Abstract][Full Text] [Related]
13. Astragaloside IV Inhibited Podocyte Pyroptosis in Diabetic Kidney Disease by Regulating SIRT6/HIF-1α Axis.
Zhang M; Liu W; Liu Y; Zhang Z; Hu Y; Sun D; Li S; Fang J
DNA Cell Biol; 2023 Oct; 42(10):594-607. PubMed ID: 37751175
[TBL] [Abstract][Full Text] [Related]
14. Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV.
Xu Z; Zhou H; Zhang Y; Cheng Z; Wan M; Qin W; Li P; Feng J; Shao S; Xue W; Guo H; Liu B
Biomed Pharmacother; 2023 Dec; 168():115752. PubMed ID: 37875045
[TBL] [Abstract][Full Text] [Related]
15. Research progress of astragaloside IV in the treatment of atopic diseases.
Yu S; Peng W; Qiu F; Zhang G
Biomed Pharmacother; 2022 Dec; 156():113989. PubMed ID: 36411656
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease.
Chen X; Li X; Cao B; Chen X; Zhang K; Han F; Kan C; Zhang J; Sun X; Guo Z
Int Urol Nephrol; 2024 Feb; 56(2):571-582. PubMed ID: 37552392
[TBL] [Abstract][Full Text] [Related]
17. Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy.
Du N; Xu Z; Gao M; Liu P; Sun B; Cao X
Drug Des Devel Ther; 2018; 12():3517-3524. PubMed ID: 30425453
[TBL] [Abstract][Full Text] [Related]
18. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.
Song G; Han P; Sun H; Shao M; Yu X; Wang W; Wang D; Yi W; Ge N; Li S; Yi T
J Int Med Res; 2018 Jul; 46(7):2883-2897. PubMed ID: 29896981
[TBL] [Abstract][Full Text] [Related]
19. Astragaloside IV ameliorates cisplatin-induced liver injury by modulating ferroptosis-dependent pathways.
Guo J; Le Y; Yuan A; Liu J; Chen H; Qiu J; Wang C; Dou X; Yuan X; Lu D
J Ethnopharmacol; 2024 Jun; 328():118080. PubMed ID: 38521426
[TBL] [Abstract][Full Text] [Related]
20. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy.
Guo H; Wang Y; Zhang X; Zang Y; Zhang Y; Wang L; Wang H; Wang Y; Cao A; Peng W
Sci Rep; 2017 Jul; 7(1):6852. PubMed ID: 28761152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
